Budget impact analysis of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma-Reference-Cited by-同舟云学术

Budget impact analysis of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma

Published:2024-04 Issue:sup3 Volume:27 Page:9-23
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Abraham Ivo¹²³⁴⁵^ORCID,Calamia Matthias⁵⁶^ORCID,Alkhatib Nimer⁵⁷⁸^ORCID,Pondel Marc⁹^ORCID,MacDonald Karen⁵^ORCID

Affiliation:

1. University of Arizona Cancer Center, Tucson, AZ, USA

2. Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ, USA

3. Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, Tucson, AZ, USA

4. Department of Family and Community Medicine, College of Medicine – Tucson, University of Arizona, Tucson, AZ, USA

5. Department of Research, MATRIX45 LLC, Tucson, AZ, USA

6. Zorginstituut Nederland (National Health Care Institute of The Netherlands), Diemen, The Netherlands

7. Department of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan

8. Path Economics, LLC, Amman, Jordan

9. Department of Medical Affairs, Coherus BioSciences, Inc, Redwood City, CA, USA

Funder

Coherus BioSciences

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2024.2379055

Reference29 articles.

1. World Health Organization International Agency for Research on Cancer. The Global Cancer Observatory: nasopharynx ; 2020. Available from: https://gco.iarc.fr/today/data/factsheets/cancers/4-Nasopharynx-fact-sheet.pdf.

2. Increasing incidence of Epstein‐Barr virus–related nasopharyngeal carcinoma in the United States

3. Cigarette Smoking, Alcohol, and Nasopharyngeal Carcinoma: A Case-Control Study Among U.S. Whites

4. Nasopharyngeal cancer in a low-risk population: defining risk factors by histological type;Vaughan TL;Cancer Epidemiol Biomarkers Prev,1996

5. Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-efficiency and budget-neutral expanded access modeling of pembrolizumab versus the novel PD-1 inhibitor toripalimab in locally advanced or metastatic nonsquamous non-small cell lung cancer;Journal of Medical Economics;2024-04